TP53 and colorectal carcinoma: experimental results indicate that TP53 inhibits dipeptidyl peptidase 4 (DPP4) activity in an independent way of transcription, which can restrain Erastin-induced ferroptosis in colorectal carcinoma (Xie et al., 2017).